Stock 001367 ZHEJIANG HAISEN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Zhejiang Haisen Pharmaceutical Co., Ltd.

Equities

001367

CNE1000061L9

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
39.18 CNY +2.00% Intraday chart for Zhejiang Haisen Pharmaceutical Co., Ltd. +1.95% -10.87%
May. 20 Zhejiang Haisen Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2023 CI
Apr. 24 Zhejiang Haisen Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2023
Capitalization 1 2,989
Enterprise Value (EV) 1 2,046
P/E ratio 26.2 x
Yield 1.14%
Capitalization / Revenue 7.52 x
EV / Revenue 5.15 x
EV / EBITDA 18 x
EV / FCF -112,757,410 x
FCF Yield -0%
Price to Book 2.39 x
Nbr of stocks (in thousands) 68,000
Reference price 2 43.96
Announcement Date 4/22/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 246.6 266.3 283.9 388.9 422.8 397.5
EBITDA 1 69.09 80.24 81.72 117.4 118.7 113.4
EBIT 1 60.82 70.92 71 105 105.2 100.9
Operating Margin 24.67% 26.63% 25.01% 27% 24.88% 25.39%
Earnings before Tax (EBT) 1 67.48 80.11 73.57 108.5 123.8 120.7
Net income 1 58.55 68.96 62.83 94 107.6 104.7
Net margin 23.74% 25.89% 22.13% 24.17% 25.46% 26.33%
EPS 2 1.210 1.350 1.230 1.840 2.110 1.680
Free Cash Flow - 16.05 31.09 44.27 -2.252 -18.14
FCF margin - 6.03% 10.95% 11.38% -0.53% -4.56%
FCF Conversion (EBITDA) - 20% 38.05% 37.7% - -
FCF Conversion (Net income) - 23.27% 49.49% 47.09% - -
Dividend per Share - - - - - 0.5000
Announcement Date 12/21/21 12/21/21 12/21/21 3/21/22 4/6/23 4/22/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 114 138 140 204 246 944
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - 16 31.1 44.3 -2.25 -18.1
ROE (net income / shareholders' equity) - 28.5% 23% 29.4% 25.9% 12.2%
ROA (Net income/ Total Assets) - 13.8% 12.5% 15.6% 12.6% 6.62%
Assets 1 - 499.9 503.2 602.1 853.6 1,582
Book Value Per Share 2 4.480 5.220 5.470 7.080 9.200 18.40
Cash Flow per Share 2 1.500 1.800 2.740 4.020 4.850 13.90
Capex 1 9.53 18 21 33.3 20.2 57.4
Capex / Sales 3.87% 6.74% 7.4% 8.57% 4.78% 14.45%
Announcement Date 12/21/21 12/21/21 12/21/21 3/21/22 4/6/23 4/22/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
ZHEJIANG HAISEN PHARMACEUTICAL CO., LTD. Stock Zhejiang Haisen Pharmaceutical Co., Ltd.
-10.87% 368M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
NOVARTIS AG Stock Novartis AG
+9.78% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 001367 Stock
  4. Financials Zhejiang Haisen Pharmaceutical Co., Ltd.